Linked Life Data

7178231

Source:http://linkedlifedata.com/resource/pubmed/id/7178231

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1983-2-14
pubmed:abstractText
In 20 patients with primary depression the urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG) was determined prior to a 4-week treatment with maprotiline 125 mg/day. Reliable data were available from 16 patients and averaged 1.35 mg/24 h. There was a trend towards a negative relationship between MHPG excretion and clinical improvement as reflected by the percent reduction in Hamilton scale scores. Responders, defined as those patients with a final score of less than or equal to 6, excreted less MHPG than partial or non-responders. Plasma maprotiline levels exhibited a significant increase between treatment days 14 and 28. They did not show a significant relationship to the reduction of total Hamilton scale scores. However, final scores of symptoms pertaining to depressive retardation were significantly higher in patients with low (less than 75 ng/ml) or high (greater than 150 ng/ml) plasma levels than in those with levels in an intermediate range.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0720-4280
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
170-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't